Ibrayeva Lyazat, Bacheva Irina, Alina Assel, Klassen Olga
Department of Internal Medicine, Karaganda Medical University, Karaganda 100012, Kazakhstan.
Medicina (Kaunas). 2025 Aug 31;61(9):1572. doi: 10.3390/medicina61091572.
Chronic lung diseases act as multi-organ conditions in which systemic inflammation, vascular dysfunction, and fibrosis intersect. The pulmo-renal continuum-functional crosstalk between lungs and kidneys-remains poorly characterized. We compared year-long changes in endothelin-1 (ET-1), galectin-3 (Gal-3), renal indices (eGFR, ACR), and quantitative CT densitometry in COPD and systemic sclerosis-associated ILD (SSc-ILD). : In this prospective observational study (January 2023-December 2024), 112 patients were consecutively enrolled (COPD, n = 58; SSc-ILD, n = 54). Assessments were performed at baseline and 12 months. ET-1 (ELISA) and Gal-3 (chemiluminescence) were measured in serum; eGFR was calculated by the creatinine-based CKD-EPI (2021) equation; ACR was photometric. High-resolution chest CT provided lung volume and parenchymal density (Hounsfield units) at six predefined axial levels per lung. Non-parametric statistics were applied: Wilcoxon signed-rank (within-group), Mann-Whitney U (between-group), and Spearman rank correlations for associations; results are reported with -values (and 95% CIs). Baseline eGFR was normal (COPD 90.37; SSc-ILD 92.4 mL/min/1.73 m). eGFR declined by 6.76% in COPD ( = 0.001) and 3.16% in SSc-ILD ( = 0.029). ET-1 increased in both cohorts but more in COPD (+83.78%, = 0.0002) than in SSc-ILD (+23.83%, = 0.0001). Gal-3 rose significantly only in SSc-ILD (+10.2%, = 0.043). FVC decreased in COPD (-4.01%, = 0.01) and was unchanged in SSc-ILD. Total lung volume declined in SSc-ILD (-6.08%, = 0.02) but not in COPD. CT density shifts were small: several slices in COPD and one slice (L6) in SSc-ILD reached statistical but not biological relevance. COPD exhibited larger vascular and renal biomarker shifts (ET-1 up, eGFR down, ACR up), suggesting systemic inflammation and early renal involvement. In SSc-ILD, biomarker and CT changes predominantly reflected pulmonary fibrosis progression with limited renal impact. Integrating biomarkers with quantitative CT may help delineate organ-specific trajectories along the pulmo-renal continuum; longer, larger studies are warranted. Limitations: This was a single-center cohort with a modest sample (58 COPD and 54 SSc-ILD) and a 12-month, two-time-point follow-up, which may not capture long-term trajectories and may limit it generalizability; larger multicenter studies with an extended follow-up are warranted.
慢性肺部疾病表现为多器官疾病,其中全身炎症、血管功能障碍和纤维化相互交织。肺-肾连续体——肺和肾之间的功能串扰——仍未得到充分描述。我们比较了慢性阻塞性肺疾病(COPD)和系统性硬化症相关间质性肺疾病(SSc-ILD)患者中内皮素-1(ET-1)、半乳糖凝集素-3(Gal-3)、肾脏指标(估算肾小球滤过率[eGFR]、尿白蛋白肌酐比值[ACR])以及定量CT密度测定的年度变化。:在这项前瞻性观察性研究(2023年1月至2024年12月)中,连续纳入了112例患者(COPD,n = 58;SSc-ILD,n = 54)。在基线和12个月时进行评估。采用酶联免疫吸附测定(ELISA)法检测血清中的ET-1,采用化学发光法检测Gal-3;通过基于肌酐的慢性肾脏病流行病学合作组(CKD-EPI,2021)方程计算eGFR;采用比色法检测ACR。高分辨率胸部CT在每侧肺的六个预定义轴向层面提供肺容积和实质密度(亨氏单位)。应用非参数统计方法:威尔科克森符号秩检验(组内)、曼-惠特尼U检验(组间)以及斯皮尔曼等级相关分析关联性;结果报告为P值(及95%置信区间)。基线时eGFR正常(COPD为90.37;SSc-ILD为92.4 mL/min/1.73 m²)。COPD患者的eGFR下降了6.76%(P = 0.001),SSc-ILD患者下降了3.16%(P = 0.029)。两个队列中的ET-1均升高,但COPD患者升高幅度更大(+83.78%,P = 0.0002),高于SSc-ILD患者(+23.83%,P = 0.0001)。Gal-3仅在SSc-ILD患者中显著升高(+10.2%,P = 0.043)。COPD患者的用力肺活量(FVC)下降(-4.01%,P = 0.01),而SSc-ILD患者的FVC无变化。SSc-ILD患者的肺总量下降(-6.08%,P = 0.02),而COPD患者无下降。CT密度变化较小:COPD患者的几片以及SSc-ILD患者的一片(L6)达到统计学意义但无生物学意义。COPD患者的血管和肾脏生物标志物变化更大(ET-1升高、eGFR下降、ACR升高),提示全身炎症和早期肾脏受累。在SSc-ILD患者中,生物标志物和CT变化主要反映肺纤维化进展,对肾脏影响有限。将生物标志物与定量CT相结合可能有助于描绘肺-肾连续体上器官特异性的变化轨迹;需要开展更大规模、更长时间的研究。局限性:这是一个单中心队列,样本量适中(58例COPD和54例SSc-ILD),随访12个月、两个时间点,可能无法捕捉长期变化轨迹,可能会限制其普遍性;需要开展更大规模的多中心研究并延长随访时间。